Methods for preparing a PEG composition by co-precipitation of two or more components to produce a substantially homogenous powder. According to some embodiments, the two or more components are at least and partially soluble in a solvent, and at least one component is a functionalized PEG. Contacting the at least two component with the solvent at least partially dissolves the components which are then co-precipitated. The resulting product is substantially homogenous, unlike product made by other methods. The PEG composition may be co-precipitated with additional compounds, such as a colorant like indocyanine green.

Methods for preparing a PEG composition by co-precipitation of two or more components to produce a substantially homogenous powder. According to some embodiments, the two or more components are at least and partially soluble in a solvent, and at least one component is a functionalized PEG. Contacting the at least two component with the solvent at least partially dissolves the components which are then co-precipitated. The resulting product is substantially homogenous, unlike product made by other methods. The PEG composition may be co-precipitated with additional compounds, such as a colorant like indocyanine green.

The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the tissue-active monomers, including monomers comprising macromolecules, provide abroad set of material choices for synthetic tissue barriers. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.

The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the tissue-active monomers, including monomers comprising macromolecules, provide abroad set of material choices for synthetic tissue barriers. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.

The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the tissue-active monomers, including monomers comprising macromolecules, provide abroad set of material choices for synthetic tissue barriers. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.

The present disclosure provides technology that can ensure excellent visibility when introducing an embolization agent and that reduces the visibility of said agent after introduction. Provided is an embolization agent having a hydrogel which contains a visualizing agent, and a reaction product of an ethylenically unsaturated monomer, a crosslinking agent, and, as necessary, a bifunctional monomer, where the swelling ratio of the embolization agent is 5-300 times, and the post-swelling CT number of the embolization agent is 50-300 HU and falls below the pre-swelling CT number of the embolization agent.

The present disclosure provides technology that can ensure excellent visibility when introducing an embolization agent and that reduces the visibility of said agent after introduction. Provided is an embolization agent having a hydrogel which contains a visualizing agent, and a reaction product of an ethylenically unsaturated monomer, a crosslinking agent, and, as necessary, a bifunctional monomer, where the swelling ratio of the embolization agent is 5-300 times, and the post-swelling CT number of the embolization agent is 50-300 HU and falls below the pre-swelling CT number of the embolization agent.

A method of producing embolic particles includes forming a master batch of embolic particles, wherein the master batch of particles includes a plurality of negatively charged loading sites. The method also includes modifying the master batch of particles to form an activated batch of particles by reacting the master patch of particles with a bridging agent. The activated batch of particles includes a plurality of activated loading sites configured to bond to a negatively charged drug.

A method of producing embolic particles includes forming a master batch of embolic particles, wherein the master batch of particles includes a plurality of negatively charged loading sites. The method also includes modifying the master batch of particles to form an activated batch of particles by reacting the master patch of particles with a bridging agent. The activated batch of particles includes a plurality of activated loading sites configured to bond to a negatively charged drug.

Devices used to restrict flow within a blood vessel are disclosed. Devices within the scope of this disclosure include a braided lattice of nitinol wires that form self-expanding enclosures of an embolic structure. The devices may further include embolic particles disposed within the enclosures. Methods of deploying the devices with the embolic particles are disclosed. Methods of manufacturing the devices with the embolic particles disposed within the enclosures are disclosed.